NCT00943579View on ClinicalTrials.gov

Open-Label Extension Study of Kuvan for Autism

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions

Autistic Disorder

Interventions

DRUG

Kuvan®

Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.

Trial Locations (1)

94304

The Children's Health Council, Palo Alto

Sponsors

Collaborators (1)

BioMarin Pharmaceutical

All Listed Sponsors

collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

The Children's Health Council

OTHER

NCT00943579 - Open-Label Extension Study of Kuvan for Autism | Biotech Hunter | Biotech Hunter